Latest News

Another myeloma drug with same target as CAR-Ts shows successful Phase II results

Without providing details, GlaxoSmithKline said its trial of BCMA-targeting belantamab mafodotin was positive. The company plans to submit for regulatory approvals later this year – potentially ahead of bluebird and Celgene’s expected filing next year for the CAR-T bb2121.

Source link

Related posts

Patient Safety Movement Foundation nomeia novo presidente do conselho e anuncia determinação para atingir a meta de reduzir a zero as mortes evitáveis de pacientes até 2030


Measuring health-related quality of life in pediatric kidney transplant recipients


STAT Plus: AstraZeneca and GSK drugs reduce risk of ovarian cancer returning, studies find


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World